Clinical and Laboratory Evaluation of Patients Diagnosed with COVID-19 Receiving Favipiravir-based Treatment
Objective:Severe acute respiratory syndrome coronavirus-2 (SARS COV-2); can lead to severe respiratory failure. In this study, factors affecting mortality in Coronavirus disease (COVID-19) patients who were hospitalized with hydroxychloroquine (HCQ), azithromycin and favipiravir treatments were inve...
Main Authors: | Burak SARIKAYA, Semiha ÇELİK EKİNCİ |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Publishing House
2020-12-01
|
Series: | Bezmiâlem Science |
Subjects: | |
Online Access: |
http://bezmialemscience.org/archives/archive-detail/article-preview/clinical-and-laboratory-evaluation-of-patients-dia/42775
|
Similar Items
-
Favipiravir Use in COVID-19 Treatment
by: Emre KARA, et al.
Published: (2021-03-01) -
Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study
by: Alotaibi M, et al.
Published: (2021-09-01) -
Mortality Predictors in Patients Diagnosed with COVID-19 in the Emergency Department: ECG, Laboratory and CT
by: Aslı Türkay Kunt, et al.
Published: (2021-06-01) -
Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
by: Rahmet Guner, et al.
Published: (2021-03-01) -
The Evaluation of Patients with Severe COVID-19 Pneumonia Who are Recieving Favipiravir Treatment
by: Servet ÖZTÜRK, et al.
Published: (2021-12-01)